Background A randomized, double-blind, multicenter study was conducted to compare the anti-tumor activity of letrozole vs. tamoxifen in postmenopausal women with ER and/or PgR positive primary untreated breast cancer
Introduction
Traditionally, primary breast cancer is initially treated surgically, with or without radiotherapy [1] . Subsequently, patients may receive adjuvant endocrine therapy and/ or chemotherapy. In recent years, several reports have described the use of hormonal therapy or chemotherapy prior to surgical resection in patients with potentially operable breast tumors [2] The choice of preoperative therapy, chemotherapy or hormonal therapy is dependent on the patient demographics and disease characteristics of the population selected Preoperative chemotherapy in primary breast cancer patients for the purpose of increasing the rate of breastconserving surgery (BCS) is accepted as an effective treatment. Disease-free survival and overall survival have been similar in these studies to those of patients in whom systemic therapy is only used after surgery [3] [4] [5] [6] . Most commonly used chemotherapy regimens are accompanied by a relatively high frequency of toxicity related to myelosuppression as well as alopecia and mucositis.
However, in elderly postmenopausal women with a limited life span and co-morbid conditions, alternative strategies to the treatment of primary breast cancer are needed In these patients, using a relatively non-toxic and well-tolerated hormonal therapy preoperatively might offer the possibility of BCS to women whose tumors may initially be judged as too large or not suitable for such surgery. Randomized studies comparing tamoxifen administered as primary therapy to surgery followed by adjuvant tamoxifen have demonstrated initial reduction in tumor size for the majority of older postmenopausal women with breast cancer without impact on overall survival; however, long-term local disease control is poor [7] [8] [9] [10] [11] . A recent meta-analysis of some of these studies, however, reported that patients randomized to initial surgery did not have a significant advantage in terms of overall survival, although there was a trend (RR0 86, P = 0.09) [12] While tamoxifen is well-tolerated, its adverse events (AEs) including vaginal discharge, increased risk of endometnal cancer and the increased incidence of thrombo-embolic events, although infrequent, are of important clinical consequence to the patient. Thus, there is a need for more well tolerated alternative therapies for postmenopausal patients with breast cancer One such important alternative treatment is letrozole, which targets aromatase, an enzyme responsible for the predominant source of estrogen in postmenopausal women. Letrozole has been shown to be more effective than tamoxifen in terms of response rates and time to disease progression in postmenopausal women as firstline treatment for locally advanced and metastatic breast cancer [13, 14] In a phase I -11 clinical study conducted in Scotland, a clinical response rate of 92% was seen in 24 postmenopausal ER positive patients whose locally advanced breast cancer was treated with letrozole for three months prior to surgery Of note, 15 patients who were considered for a mastectomy at baseline had sufficient tumor regression to allow BCS [15] . The pilot study led to the initiation of a multinational, randomized, doubleblind study designed to compare the efficacy of preoperative letrozole with preoperative tamoxifen for postmenopausal women with ER and/or PgR positive breast cancer ineligible for BCS The results of this study are reported here
Patients and methods

Study design
This phase llb-III study was a multinational, double-blind, doubledummy, randomized, parallel-group study of once daily doses of letrozole 2 5 mg or tamoxifen 20 mg in postmenopausal women with ER and/or PgR positive primary invasive breast cancer Patients were randomly assigned letrozole or tamoxifen according to a predetermined computer-generated randomization list using permuted blocks so that treatments were balanced within each country No stratification on baseline characteristics was performed Patients received either letrozole 2 5 mg or tamoxifen 20 mg orally once daily for four months prior to surgery unless the patient was withdrawn earlier due to progressive disease (PD). an adverse event, or patient/investigator request Surgery was scheduled four months from the date the patient received her first treatment to ensure that there was no interval between the last study treatment day and the patient's operation Patients were considered to have completed the study when they had received four months of treatment and had been assessed for surgery Treatment of the patient following surgery was at the investigator's discretion (Figure 1 ) All patients are being followed for the development of local recurrence, distant metastasis and survival for five years post-surgery In addition, a correlative science study was conducted in which tumor biopsies and blood samples had to be taken from all patients prior to therapy and at the end of treatment for the purpose of generating a unique database from which changes in molecular markers occurring during hormone therapy could be identified [16] 
Study population
Eligible patients were poslmenopausal women with untreated primary breast cancer, confirmed by core needle biopsy, with 10% nuclear and ultrasound Tumors were considered inoperable or not amenable for BCS For those patients with smaller tumors (i e T2 at the time of entry into the study) a comment from the investigator was required to explain why these patients were not considered eligible for BCS at study entry Most of the patients were not eligible for BCS because of a non-favorable ratio tumor size/breast size Adequate hematological, renal and liver function and a life expectancy of at least six months were also required All patients provided written informed consent and institutional review board approvals were obtained at each center Exclusion criteria included prior exposure to letrozole or tamoxifen. uncontrolled endocrine or cardiac disease, bilateral or inflammatory breast cancer, distant metastasis, other malignant diseases (except treated in situ cervical carcinoma or adequately treated basal or squamous cell carcinoma of the skin) Co-administration of other cancer treatments was not allowed and hormone replacement therapy must have been discontinued at least two weeks prior to sludy start
Study assessments
At the initial study visit, demographics and a complete medical history were recorded for each patient At that time eligible patients underwent a physical examination including a review of current medical conditions, cancer diagnosis, and postmenopausal status The clinical stage of the tumor was determined by measuring the primary breast lesion and the axillary lymph nodes (if applicable) by physical examination Mammography, breast ultrasound, and ER and PgR status were also obtained Afterwards (but prior to start of trial medication) core biopsies for the correlative science protocol were taken Patients were assessed for tumor response according to the WHO criteria [17] by monthly clinical examination Evaluation of AEs and concomitant medications/therapies were also assessed at each monthly visit Tumor response was evaluated by ultrasound at the end of months 2 and 3 In case of suspicion of early progression ultrasound was performed at the end of month 1 At the final visit, ultrasound, mammography, and assessment for surgery were performed and sampling for the correlative science protocol was repeated
Study endpoints
The primary efficacy endpoint was overall objective response and was defined as the percentage of patients in each treatment arm with a complete response (CR) or a partial response (PR) as determined clinically by breast palpation Response categories were CR, PR, no change (NQ, progressive disease (PD) or not assessable/not evaluable (NA/NE) Palpable ipsilateral axillary lymph nodal involvement downgraded a clinical CR in the tumor to PR The secondary efficacy endpoints were the percentage of patients who underwent BCS, the response rate (CR + PR) determined by mammography at four months, and the response rate (CR + PR) determined by ultrasound at four months The number of pathological CRs at surgery was to be described
The main criterion for tolerabihty was the occurrence of AEs, assessed at monthly intervals The safety and tolerability of the letrozole treatment group was based on the frequency and seventy of AEs compared to the tamoxifen treatment group The severity was graded according to the National Cancer Institute Common Toxicity Criteria [18] 
Statistical methods
Based on the primary efficacy endpoint (overall objective response rate determined by clinical palpation) a sample size of 302 patients calculated by the Fleiss formula [19] was considered adequate to detect a difference of 15% between letrozole and tamoxifen at a 5% significance level (2-sided) and with 80% power Based on a review of early data on neoadjuvant tamoxifen use, a response rate of 65% was anticipated on the tamoxifen arm [20] Treatments were compared using the MantelHaenzsel chi-square test stratified by baseline tumor size (T2, >T2) and nodal involvement (NO, > NO) The secondary endpoints, the proportion of patients in each treatment group with a CR or PR assessed by ultrasound or mammography, as well as the number of patients in each treatment group who underwent BCS, were analyzed using the same statistical test An exploratory logistic regression analysis was conducted to examine the influence of baseline tumor size (T2, >T2), nodal involvement (NO, > NO) and age (<70 years, >70 years) on overall objective response determined by clinical palpation as well as on BCS If a patient discontinued study treatment earlier than four months (± 2 weeks), and had a last assessment of PD, the earlier diagnosis of PD was counted If a patient discontinued study treatment earlier than four months (± 2 weeks) for other reasons, then her final response was considered NA/NE for the analysis All patients with a diagnosis of breast cancer documented at study entry who took at least one dose of study medication and who were treated at good clinical practice (GCP) compliant centers were included in the efficacy intent-to-treat (ITT) population Safety analyses excluded patients who never received study drug and patients in GCP non-compliant centers
Results
Three hundred thirty-seven patients from 55 centers in 16 countries were enrolled in the study between March 1998 and August 1999 Thirteen patients (3%) were excluded nine patients from two GCP non-compliant centers, one patient who never took study medication and three patients without histological or cytological evidence of breast cancer, leaving a total of 324 patients, 154 receiving letrozole and 170 receiving tamoxifen in the ITT population. The slight imbalance in the number of patients in each treatment group was due to a number of centers that recruited 1-3 patients, giving rise to a number of 'incomplete blocks' Baseline characteristics of both treatment groups were well balanced according to age, race, hormone receptor status, and tumor/nodal stage of disease Protocol violation (Table 1) As required by the protocol, none of the patients were considered to be candidates for BCS and similar numbers in each group were considered to have inoperable tumors (20 patients on letrozole and 24 patients on tamoxifen) at baseline. Fewer patients in the tamoxifen group completed the study 23 patients on letrozole and 41 patients on tamoxifen discontinued prematurely. The main reason for premature discontinuation was disease progression (13 patients on letrozole and 21 patients on tamoxifen). Reasons for discontinuation other than disease progression were adverse events in four cases, abnormal lab/test results in two cases, protocol violations in 11 cases, withdrawal of consent/lost to follow up in 12 cases and administrative problems in one case.
Efficacy
Evaluation of the primary efficacy endpoint (overall objective response determined by clinical palpation) revealed that the overall objective response (CR + PR) rate was statistically significantly superior in the letrozole group, 55% compared to tamoxifen, 36% (P < 0 001) ( Table 2) . Median time to response was 66 days in the letrozole group and 70 days in the tamoxifen group. Logistic regression demonstrated that the odds of achieving a clinical response (CR + PR) were more than twice as high with letrozole than with tamoxifen (odds ratio 2.23, P -0 0005). Only treatment assignment influenced the odds of achieving a CR or PR There was no relationship with initial tumor size (P = 0 22), nodal involvement (P = 0.46), or age (P = 0.95). Clinically 12% of the letrozole patients and 17% of the tamoxifen patients progressed while 24% of patients on letrozole and 35% of patients on tamoxifen had stable disease. Letrozole was also more effective when response was determined by ultrasound, 35% vs. 25% (P = 0.042) and mammography, 34% vs. 16% (P < 0.001) (Table 3) .
Significantly more BCS took place on the letrozole arm than the tamoxifen arm (45% vs. 35%, P -0.022) Patients presenting with T2 tumors, compared with all other T stages, had an odds ratio for BCS of 4.56 (P = 0.0001) Apart from tumor size, the only other factor that influenced the odds of undergoing BCS was treatment (odds ratio 1.71, P = 0.03) In total, 50 patients (15%) did not undergo surgical resection following treatment with study medication 12% in the letrozole group and 18% in the tamoxifen group Twenty patients did not have surgery because of PD and they went on to receive other therapies (chemo-or radiotherapy). Six patients were inoperable and remained inoperable while 13 patients refused surgery. Five patients had medical conditions that contraindicated surgery. The remaining six patients were withdrawn from the study for various reasons (negative receptor status, increase in tumor markers, adverse events, bone metastases, no hospital bed available at proposed time of surgery) Pathological CR in the primary breast lesion was shown in two patients in the letrozole group and in three patients in the tamoxifen group, and microscopic residual foci of cancer (pathological stage Tla) were observed in two patients in each group. Of those patients with a pathological CR in the primary breast lesion, only two (one in each treatment group) had no positive nodes at surgery
Safely
The nature and frequency of commonly reported AEs was the same for the letrozole and tamoxifen groups (57% in each group), the most commonly reported AEs related to study treatment being hot flushes and nausea (Table 4 ) Serious adverse events suspected of being related to treatment were reported in one patient in each treatment group: one patient in the letrozole group was discontinued for a pulmonary embolism, and one patient in the tamoxifen group was discontinued for erythema multiforme No death occurred during the preoperative therapy or in the six-week period following study treatment.
Discussion
This paper describes the first large randomized doubleblind clinical trial comparing two endocrine agents as preoperative treatment for primary breast cancer. As strictly a preoperative study, with a relatively short preoperative treatment period, this study is distinct from earlier primary endocrine therapy investigations that delayed surgery until local disease progression [7] [8] [9] [10] [11] The results of this study clearly showed that four months of preoperative letrozole is a more active preoperative regimen than tamoxifen in the patient population studied.
Although the response rate determined by clinical examination in the tamoxifen arm is lower than the previously reported response rate of 65% on tamoxifen [20] , the response rate observed in this large multinational trial falls within the range previously reported in the literature (21% to 59%) from large multicenter trials [7] [8] [9] [10] . The similar time to response observed in both treatment arms indicates that the preoperative treatment period of 4 months was not biased in favor of either letrozole or tamoxifen.
In this large randomized trial an independent review of radiologic findings was not performed This study was a double-blind randomized trial and therefore this was felt sufficient to minimize the investigator bias in the assessment of responses. The discrepancies between the response rates using the different methods are not unexpected, given the different sensitivities and the operator-dependent variability [21] . The low response rates observed with ultrasound and especially with mammography are not unusual for large multinational, multicenter studies such as the study reported here They can be partially explained by missing ultrasound and/or mammographic assessments at the end of the trial treatment, leading to a number of patients with a nonevaluable response on ultrasound and/or mammography and thus diluting the overall objective response rate. However, the consistent superiority of letrozole over tamoxifen independent of the methodology used, clearly shows the robustness of the results. Treatment with letrozole also resulted in a higher number of patients who underwent BCS after four months of treatment Earlier systemic treatment might reduce the likelihood that resistant clones will emerge spontaneously, and can be used as an in vivo test for treatment sensitivity. If preoperative systemic treatment fails, then this might be predictive of the response to this therapy postoperatively. There are clinical data that support the hypothesis that the chemotherapeutic sensitivity of primary tumors and micrometastases are similar [22] [23] [24] [25] .
Direct comparison of the outcome of this study with results seen with preoperative chemotherapy is difficult, since most preoperative chemotherapy studies have not reported data specifically on postmenopausal patients with ER and/or PgR positive tumors. Preoperative chemotherapy is considered to have higher response rates (65%-98%) than preoperative hormonal therapy [26] [27] [28] . However, there are suggestions that the activity of preoperative chemotherapy may be reduced in postmenopausal patients with ER and/or PgR positive tumors, at least with respect to doxorubicin-containing regimens [29] . A letrozole response rate of 55% is therefore highly encouraging, particularly given the simplicity and low toxicity of the regimen.
After preoperative treatment with letrozole, 45% of women initially not eligible for BCS became candidates for BCS. This number may appear low especially when compared to preoperative chemotherapy studies and taking into account the fact that about 50% of the patients had T2 tumors at study entry. However, none of the patients in this study were eligible for BCS at entry while most preoperative chemotherapy studies allowed patients with small tumors (<2 cm) and/or patients eligible for BCS at study entry to be enrolled [3] .
Preoperative chemotherapy has been shown not to affect adversely overall time to progression and survival [3] [4] [5] [6] This study was not designed to assess differences in time to event. However, patients in this study were only treated preoperatively for a short time span (four months) after which they underwent surgery, followed by the appropriate adjuvant endocrine therapy with or without chemotherapy. Letrozole demonstrated superiority over tamoxifen in overall objective response rate and rate of breast-conserving surgery. Letrozole is a reasonable alternative to preoperative chemotherapy for postmenopausal women with ER positive disease in clinical situations where the low toxicity of the regimen is considered an advantage, for example, in women over 70 Further investigations to assess long-term endpoints of this new clinical approach are needed. Presently, a randomized study in the adjuvant setting comparing letrozole and tamoxifen is under way. 
